Congratulations to the RESI South Innovator’s Pitch Challenge Winners! 

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

At the inaugural RESI South, we had 43 companies participate in the Innovator’s Pitch Challenge (IPC). These finalist companies pitched to an audience and fielded questions from a panel of investor judges and exhibited a poster showing their technology at the conference. Many of the pitch companies were representative of the seven southern states that were selected by the SE Life Science Investor Coalition and the entities that make up the investor group; Bio Alabama, Bio Florida, Georgia Bio, Life Science Tennessee, NC Life Sciences Organization, SC Bio and Virginia Bio.

Registered RESI attendees (startup executives, early-stage investors, and industry experts), ‘invest’ or vote for their favorite IPC company with RESI cash provided, based on the pitch company’s poster board displayed at RESI’s exhibit hall and their performance in their pitch session.

Life Science Nation is pleased to share the winners who received the most votes during the RESI South. Congratulations to the winners!

1st Place – SiNON Nano Sciences

At SiNON Nano Sciences we specialize in a patented Carbon Nano Particle (CNP) drug delivery system, specifically designed for targeted treatment of Central Nervous System (CNS) diseases. Our unique release mechanism sets us apart in the market. Our tunable platform delivery system can encapsulate multiple therapeutics, including biologics weighing up to 500kD, and efficiently deliver them across the blood-brain barrier (BBB) to treat various neurological diseases. One of the key advantages of our CNPs is that they only open at the site of the disease, enabling higher concentrated doses while significantly reducing overall toxicity and enhancing therapeutic efficacy. Additionally, our carbon-based nanoparticles go undetected by the immune system.

1st-place

Cameron Hurlburt, Director of Business Development – West Coast (US), LSN | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series | Afreen Allam, CEO, SiNON Nano Sciences | Laura Gunter, President, North Carolina Life Sciences Organization


2nd Place – Sanguina

Sanguina is a B2B company with a digital health platform and test kits for point of care and home-based diagnostics that measure key biomarkers of wellness and chronic disease.

The first release on the platform, AnemoCheck, is for anemia management and consists of a patented and FDA-cleared home test kit that uses a fingerstick and smartphone app (patent pending and trade secret algorithms) that noninvasively estimates hemoglobin level from a “fingernail selfie”. Anemia is defined as low hemoglobin levels and is a biomarker of disease/treatment progression. The platform is designed to serve clinical trial, point-of-care and home testing markets for those at high risk of anemia via pharmaceutical, supplement, pharmacy and telehealth B2B customers. Specifically, Sanguina focuses on development of tests for biomarkers that are associated with chronic diseases, often associated with treatments, that have traditionally been inaccessible or invasive.

2nd-place

Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series | Erika Tyburski, CEO, Sanguina | Maria Thacker, President & CEO, Georgia Bio


3rd Place – Liquet Medical

Liquet Medical is a development stage medical device company. Their first product to market will be the Versus™ Catheter – a localized drug delivery catheter to treat blood clots in the lungs. This device allows for a personalized approach to each patient through real-time biometric data monitoring. It will also speed time-to-treatment and lower hospital costs.

3rd-place

Momo Yamamoto, Investor Research Analyst, LSN | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series | John Schindler, CEO & Co-Founder, Liquet Medical | John Newby, CEO, Virginia Bio

If you’re interested in the next upcoming Innovator’s Pitch Challenge, you can apply for the RESI Europe 2024 IPC taking place June 17-19 with a 1-day in-person conference follow by 2-day virtual partnering at Hilton Diagonal Mar Barcelona in Barcelona, Catalonia, Spain. Applications are accepted on a rolling basis, so get your application submitted today!

RESI Europe registration opens at super early bird rates. Register now to save $500 by Friday, April 12.

RESI-Europe-2024-Banner-1100pxw

RESI-Boston-2024-September-1100pxw

Redefining Early Stage Investment (RESI) is returning to Europe!

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

RESI will bring over 300 global investors and licensing partners to Barcelona for 1 day in person on June 17 and 2 days of virtual partnering June 18-19. Super Earlybird registration is now open until April 12th, so register now to save 500€. The RESI conference series is a partnering conference that connects start-ups and early-stage investors and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is a unique and powerful tool for sourcing assets and advancing innovation across early-stage life science and healthcare.

Startups are also encouraged to apply to pitch in the Innovator’s Pitch Challenge (IPC) at RESI Europe. The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage life science and healthcare companies to gain additional exposure to conference attendees and pitch directly to a panel of judges, featuring active investors and industry experts.

Life Science Nation looks forward to hosting RESI in Barcelona, a top event destination in Europe, and June is the best time of year to visit. Long days and amazing outdoor dining spots make the après-conference unforgettable, and you can’t miss the emblematic Modernist treasures like Gaudi’s Sagrada Familia cathedral or the Paseig de Gracia district. Take advantage of the opportunity to see this amazing city on the Mediterranean.

To get prepared for RESI Europe, LSN will be offering the following FREE WEBINARS:

April 16, 2024 | 16:00 CET / 10:00 AM Eastern / 07:00 AM Pacific

Preparing for the Innovator’s Pitch Challenge (IPC) – Sign Up

Maximizing your exposure to investors is critical to a successful fundraising campaign, and participating in pitch events plays a large role in that. The RESI Innovator’s Pitch Challenge has been designed to give companies a platform to promote their companies, practice their pitch, and get feedback from a panel of relevant investors and industry experts. Join this session to learn what you can gain from participating in the IPC and how to apply.


May 2, 2024 | 16:00 CET / 10:00 AM Eastern / 07:00 AM Pacific

Presenting to Investors: Compelling Story vs Pitch Deck – Sign Up

The most successful entrepreneurs are always the best storytellers. Finding a way to formulate your company’s unique story naturally and portraying it through multiple modalities, whether a 1-minute elevator pitch or a 12-slide pitch deck, is one of the most effective ways to get potential investors and partners on board with your value proposition. This bootcamp will cover the importance of entrepreneurial agency, finding your voice, and developing a compelling narrative for the different players that will emerge along a deal chain, and language tools to refine your hook.


May 14, 2024 | 16:00 CET / 10:00 AM Eastern / 07:00 AM Pacific

The LSN Event Partnering Process – Sign Up

Attending partnering events is a crucial component of a successful fundraising campaign. Learn more about our proven successful strategy and how to craft your messages from your initial outreach and each follow-up message after that.


June 11, 2024 | 16:00 CET / 10:00 AM Eastern / 07:00 AM Pacific

Investor Fireside Chat – Sign Up

This Fireside Chat will feature investors representing funds focusing on early-stage life science companies. Find out more about these funds joining the LSN ecosystem.

Hope to see you in Barcelona!

RESI-Europe-2024-Banner-1100pxw

RESI-Boston-2024-September-1100pxw

Upcoming Sponsorship Opportunities for RESI Europe & RESI Boston 

By Max Braht, Business Development Manager (USA Midwest & Canada), LSN

Max-Braht-Headshot

Life Science Nation (LSN)’s successful Redefining Early Stage Investments (RESI) Conference series is prepping for our next two conferences. The partnering-focused conference series will be taking place in Barcelona, Spain on June 17 before returning to Boston, Massachusetts on September 25. These two events will bring together a global group of startups, investors, and strategic partners throughout the early-stage life science and healthcare ecosystems.

Now is the time to start planning your impactful RESI exhibitor and sponsorship packages to engage directly with the hundreds of participating RESI attendees. For service providers, tech hubs/ accelerators, investor syndicates, or any other group looking to form a meaningful connection with early-stage startups or strategic partners, RESI is the perfect opportunity.

Please see our Sponsorship Brochure (above) for more information on how our sponsorship or exhibitor opportunities can help you meet your goals. For more information on how to become a RESI sponsor, please reach out directly to the LSN Business Development Team. We look forward to seeing you soon at one of our upcoming RESI events!

RESI-Europe-2024-Banner-1100pxw

RESI-Boston-2024-September-1100pxw

Hot Investor Mandate: Venture Arm of Global Pharmaceutical Seeks Innovative Therapeutics Companies in Oncology, Neurology, and Rare Diseases

A venture capital arm of a global pharmaceutical company with a market cap exceeding $8 million, is actively investing in the early-stage healthcare sector. The firm focuses on seed-stage opportunities, with the initial investment range broadly, spanning up to several million. The firm is interested in opportunities globally with a focus in the US. The firm is open to both leading and co-investing and will consider board seats when leading the round. While the firm is mostly financial driven, the firm is able to bring in the strategic perspective if deemed necessary. 
 
The firm seeks companies with innovative sciences addressing highly unmet needs. The firm is focused on therapeutic, including cell and gene therapy, small molecules, radiopharmaceuticals, CRISPR, and data-driven technologies such as AI-driven drug discovery. The firm is interested in oncology, neurology, and rare diseases. Less invasive diagnostic technologies are also within the scope. The firm mostly works with companies in the preclinical to phase I stages. 
 
The firm focuses on finding promising science backed by strong IP. As an active investor, the firm supports portfolio companies through its extensive network and resources. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Mandate: Angel Investment Group Invests in Life Science Companies Looking to Expand Into the China Market, Focusing on Medtech Companies

A global angel investment group was created to leverage cross-pacific business opportunities by investing in early stage life science and healthcare companies, with an Asia connection. The firm invests in companies that are interested in performing development work in China, or commercializing their products in Asia;  the firm makes use of relationships with Asia-based life science service providers to guide portfolio companies through the development process , and also assists companies with the Chinese regulatory process. The firm is pre-venture capital and can contribute business, scientific and regional expertise to companies to improve probability for success. 
 
The firm will consider opportunities across the life science space, and is primarily focused on diagnostics and devices but also invests in therapeutics and life science tools.  The firm generally invests in companies with products with strong animal data, and which are addressing a significant health problem in China (such as cancer, cardiovascular and metabolic diseases, infectious diseases, and also CNS disorders in some circumstances).  Companies which have already attained approval in a market outside China may be of interest. 
 
The firm invests in early stage deals.  The firm only invests in companies that are interested in performing development work in China, or commercializing their products in China; the firm makes use of relationships with China-based life science service providers to guide portfolio companies through the development process and obtain matching government funds in China, and also assists companies with the Chinese regulatory process. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Mandate: Impact Investor Interested in Investing in Global Life Science Technologies Focused on Pediatric Indications 

An impact investor focused on pediatric indications is willing to invest in companies in therapeutics, diagnostics, medical devices or digital health that help improve pediatric care. As an impact fund, the firm donates 10% of the General Partner’s Carry Interest to fund pediatric research. The firm generally makes initial investments of $3-5M and will invest globally. The firm looks to invest in 12-15 companies out of their first fund. 
 
Within pediatric indications, the firm is interested in Oncology, Infectious Diseases and select Rare/Orphan indications. The firm will consider any technology that helps move care forward in these areas, either directly, as a therapeutic or other treatment device or diagnostic, or indirectly, as a digital health technology that helps support care or complements treatment. For therapeutics, the firm will invest in companies that are 12-18 months from IND. For diagnostics and medical devices, the firm would like to see a proof of concept or prototype. For digital health, some post pilot sales or evidence of market traction is preferred, as is a partnership with a strategic partner, with validation of the technology. 
 
The firm can lead or co-invest, and looks to be a board observer for every portfolio company. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Mandate: VC Invests in Pre-Seed and Seed Stage CNS Therapeutics and Neurotech Companies Based in the US

Established in 2021, a USA-based venture capital firm is specialized in investments within the neurotech and psychedelics sectors. The fund actively participates in pre-seed to seed financing rounds, with an initial investment averaging around $200k and the possibility of subsequent investments. The firm actively seeks opportunities in the United States. 
 
The firm actively seeks opportunities in psychoactive therapeutics, CNS therapeutics, neurotech, and techbio. The firm has a neuro focus, and is interested in technologies/products related to CNS disorders, neurodegenerative diseases, neurostimulation and modulation, psychoactive pharmacology, etc. The firm typically invests in drug/therapeutics and medical devices but not so much in digital health. Additionally, the firm looks for cutting edge technologies that demonstrate true, step change or cornerstone innovation instead of incremental improvements on best-in-class technologies. 

The firm is an active investor that supports their portfolio companies with their network and resources. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.